Home » Authors » James Etheridge

Articles by James Etheridge

French Start-Up ObeTherapy Gains Funds For Obesity Work

Nov. 27, 2002

By James Etheridge

French Start-Up ObeTherapy Gains Funds For Obesity Work

Nov. 27, 2002

By James Etheridge

MAT Biotech Secures 1.25M For Antibody Developmen

Nov. 27, 2002

By James Etheridge

Synt:em, Probiodrug Partner To Develop Multiple Sclerosis Drug

Nov. 20, 2002

By James Etheridge

GenOway, CopyRat Collaborate To Develop Rat Disease Models

Nov. 20, 2002

By James Etheridge

Synt:em, Probiodrug Partner To Develop Multiple Sclerosis Drug

Nov. 20, 2002

By James Etheridge

GenOway, CopyRat Collaborate To Develop Rat Disease Models

Nov. 20, 2002

By James Etheridge

Serono Acquires 92 Percent of Genset, Collaborates with IVAX

Nov. 13, 2002

By James Etheridge

Serono Acquires 92 Percent of Genset, Collaborates with IVAX

Nov. 13, 2002

By James Etheridge

Avidis Closing EUR1.7M Round To Develop Peptides Technology

Nov. 6, 2002

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 13, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 13, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.